Phase 1

This section includes the details for Phase I of RARE IMPACT

Click on ‘Phase I’ in the menu to find all the details for this phase of the initiative.

The RARE IMPACT initiative Phase I aims to identify and validate the challenges to patients’ access to gene and cell therapies through engagement with HTA agencies, regulatory bodies, payers, patient groups, clinicians, manufacturers and other experts across Europe.